Business Description
Biodesix Inc
NAICS : 541380
SIC : 8734
ISIN : US09075X2071
Share Class Description:
BDSX: Ordinary SharesTotal Employee Number:
334Description
Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.36 | |||||
Equity-to-Asset | 0.1 | |||||
Debt-to-Equity | 7.84 | |||||
Debt-to-EBITDA | -3.91 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | -5.51 | |||||
Beneish M-Score | -2.73 | |||||
WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -13.6 | |||||
3-Year EBITDA Growth Rate | 50.8 | |||||
3-Year EPS without NRI Growth Rate | 44.9 | |||||
3-Year FCF Growth Rate | 48.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 38.36 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 24.68 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 91.86 | |||||
9-Day RSI | 85.87 | |||||
14-Day RSI | 80.11 | |||||
3-1 Month Momentum % | 1.44 | |||||
6-1 Month Momentum % | 117.16 | |||||
12-1 Month Momentum % | 167.62 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.82 | |||||
Quick Ratio | 2.82 | |||||
Cash Ratio | 1.76 | |||||
Days Sales Outstanding | 35.17 | |||||
Days Payable | 68.87 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -28.6 | |||||
Shareholder Yield % | -16.92 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 82.08 | |||||
Operating Margin % | -25.91 | |||||
Net Margin % | -33.26 | |||||
EBITDA Margin % | -19.08 | |||||
FCF Margin % | -26.27 | |||||
OCF Margin % | -25.85 | |||||
ROE % | -932.07 | |||||
ROA % | -35.92 | |||||
ROIC % | -38.4 | |||||
3-Year ROIIC % | 254.48 | |||||
ROC (Joel Greenblatt) % | -83.67 | |||||
ROCE % | -32.69 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 1.99 | |||||
PB Ratio | 25.93 | |||||
EV-to-EBIT | -12.01 | |||||
EV-to-Forward-EBIT | -7.73 | |||||
EV-to-EBITDA | -15.69 | |||||
EV-to-Revenue | 2.99 | |||||
EV-to-Forward-Revenue | 2.29 | |||||
EV-to-FCF | -11.4 | |||||
Price-to-GF-Value | 1.11 | |||||
Earnings Yield (Greenblatt) % | -8.33 | |||||
FCF Yield % | -10.45 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:BDSX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Biodesix Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 96.096 | ||
| EPS (TTM) ($) | -4.06 | ||
| Beta | -0.4883 | ||
| 3-Year Sharpe Ratio | 0.09 | ||
| 3-Year Sortino Ratio | 0.14 | ||
| Volatility % | 96.05 | ||
| 14-Day RSI | 80.11 | ||
| 14-Day ATR ($) | 1.584134 | ||
| 20-Day SMA ($) | 16.586 | ||
| 12-1 Month Momentum % | 167.62 | ||
| 52-Week Range ($) | 5.006 - 23.29 | ||
| Shares Outstanding (Mil) | 10.36 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Biodesix Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Biodesix Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-03 16:30 | In 130 days | ||
| Third quarter earnings results for 2026 | 2026-11-03 | In 129 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-07 16:30 | In 42 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 41 days | ||
| William Blair 46(th) Annual Growth Stock Conference | 2026-06-03 14:00 | 15.44 (+0.59%) | ||
| General meeting for 2026 | 2026-05-19 13:00 | 14.25 (+1.14%) | ||
| First quarter earnings conference call for 2026 | 2026-05-04 16:30 | 11.08 (+1.19%) | ||
| First quarter earnings results for 2026 | 2026-05-04 | 11.08 (+1.19%) | ||
| Barclays 28th Annual Global Healthcare Conference | 2026-03-11 12:00 | 18.72 (-4.15%) | ||
| TD Cowen\'s 46th Annual Health Care Conference | 2026-03-03 14:30 | 15.75 (+8.46%) |
Show
Entries
Biodesix Inc Frequently Asked Questions
What is Biodesix Inc(BDSX)'s stock price today?
The current price of BDSX is $23.27. The 52 week high of BDSX is $23.29 and 52 week low is $5.01.
When is next earnings date of Biodesix Inc(BDSX)?
The next earnings date of Biodesix Inc(BDSX) is 2026-08-07 Est..
Does Biodesix Inc(BDSX) pay dividends? If so, how much?
Biodesix Inc(BDSX) does not pay dividend.
Guru Commentaries on NAS:BDSX
No articles.
Press Release
Articles on Biodesix Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers